A study has compared the outcomes of patients receiving a permanent polymer zotarolimus-eluting stent and those receiving a polymer-free amphilimus-eluting stent. The results reportedly show noninferiority of the polymer-free stent at one year, including in patients with diabetes. The study's findings are part of a broader discussion on the effectiveness of different types of drug-eluting stents in treating coronary artery disease.